Naslov
Proteomics in Biomedical Research and Translational Medicine

Autori
Grgurević, Lovorka

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni

Skup
1st Workshop on Mass Spectrometry in Life Sciences

Mjesto i datum
Zagreb, Hrvatska, 24.11.2022. - 26.11.2022

Vrsta sudjelovanja
Predavanje

Vrsta recenzije
Nije recenziran

Ključne riječi
proteomics, translational medicine

Sažetak
A significant proportion of basic proteomic research is directed towards the clinic, largely aimed at the identification of proteins as potential biomarkers of pathological conditions. Reliable protein profiling is of particular importance in the field of plasma biomarker research where selected proteins must be consistently identified and quantified in large patient cohorts. As a first step, databases of existing plasma proteomes can serve as a valuable basis for the characterization of previously identified plasma biomarker candidates. As they are a non-invasive biological samples, blood and urine are commonly used for analysis. However, the research of human plasma/serum is challenging because a large number of parameters must be satisfied in order to validate a certain molecule as a biomarker. Other samples used in clinical studies include solid tissues, a range of other body fluids and samples from genetic animals models and cell lines. A common example is the use of mass spectrometry-based proteomics as a tool to study the biological changes occurring in cancer/metastasis. Such basic scientific research aimed to discover potential biomarker candidates, is often collaborative in nature, since clinicians collaborate with the academia. Biopsies from sites affected by primary disease such as tumours, cysts or transformed organs can be obtained directly from patients. Standardized protocols and working algorithms defining sample collection, processing and storage are essential for obtaining reliable and reproducible results. They are further processed to obtain the first round of candidate molecules, specific for a pathological condition. It is of the utmost importance that the study leader facilitates mutual communication and understanding between different disciplines and provides regular feedback on study progress. The use of high throughput protein assays in the clinical setting and the advancement of proteomics-based technologies have raised expectations in the search for new protein biomarkers. However, to date, progress has been limited due to lack of an effective technological platform, poorly defined guidelines for determining groups of clinical samples, no standardized procedures for biomarker development, and quality assessment of performed studies. Successful production of diagnostic tests should be based on a clear technical and conceptual plan. The goal of the study should be to solve a clearly defined clinical question with an appropriate study design, which is a prerequisite for biomarker discovery that connects the joint work of clinical and basic research.

Izvorni jezik
Engleski

POVEZANOST RADA